PRospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With ChemoradIotherapy Followed by cONsolidation Therapy With Durvalumab (PRECISION)
Conditions: Oncology; Biomarker; NSCLC, Stage III; Durvalumab; Chemoradiotherapy Intervention: Other: Non-interventional Sponsors: LMU Klinikum; Department of Internal Medicine V, Thoracic Oncology Centre Munich, LMU Munich, Munich, Germany; Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany; Asklepios Lung Clinic, Munich-Gauting, Germany; Department of Radiology, University Hospital, LMU Munich, Munich, Germany; Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany; Institute for Medical Information Processing, Biometry and Epidemiology, LMU München, Munich, Germany; Department of Medicine II, University Hospital, LMU Munich, Munich, Germany; Immunoanalytics Research Group Tissue Control of Immunocytes, Helmholtz Center Munich, Munich, Germany Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Allergy & Immunology | Cancer & Oncology | Epidemiology | Genetics | Germany Health | Hospitals | Internal Medicine | Non-Small Cell Lung Cancer | Nuclear Medicine | Pathology | Radiology | Research